<div id="readability-page-1"><div>By Adria Calatayud Shares in argenx fell after the pharmaceutical company said it would stop late-stage trials for an experimental drug to treat thyroid eye disease due to lack of efficacy. In European afternoon trading Monday, Brussels-listed shares in argenx were down 6.9% at 701.60 euros, but have risen 17% since the start of the year. The Amsterdam-based company said it would discontinue the trials for the drug, Vyvgart subcutaneous, as a treatment for adults with thyroid eye disease, an autoimmune disease that can lead to vision loss in severe cases, the company said. The decision followed a recommendation from an independent data-monitoring committee and was based on a review of data from a planned futility analysis after 24 weeks in the studies, argenx said. The analysis showed the studies didn't meet argenx's desired outcome, it said. The drug showed a favorable safety and tolerability profile, with no new safety signals identified, the company added. This marks a surprising failure for Vyvgart and removes what was likely to be a major catalyst for its shares next year, analysts at UBS wrote in a note to clients. Nevertheless, data from previous studies for argenx's other late-stage trials are more robust, the analysts said. Write to Adria Calatayud at adria.calatayud@wsj.com (END) Dow Jones Newswires12-15-25 0915ET</div></div>

ARGX

Argenx 的股价下跌了 6.9%，原因是该公司宣布将停止其甲状腺眼病药物 Vyvgart 皮下注射的后期临床试验，原因是缺乏疗效。该决定是基于无效性分析的建议。尽管如此，该药物显示出良好的安全性。瑞银分析师指出，这一失败消除了明年股价的一个主要催化剂，但其他后期临床试验仍然稳健

Argenx 公司在放弃眼病药物试验后，股价下跌